When COVID-19 Coagulopathy Masks Thrombotic Thrombocytopenic Purpura: An Atypical Presentation with Multifocal Cerebral Infarction - A Case Report

The Body's Traffic Jam and the Invisible Brake

Imagine your bloodstream as a bustling city highway. Normally, cars (red blood cells) and delivery trucks (platelets) zip along smoothly, guided by traffic lights and road signs. But sometimes, a glitch occurs in the city's control center. In a condition called Thrombotic Thrombocytopenic Purpura, or TTP, a specific "traffic cop" enzyme called ADAMTS13 goes missing. This enzyme's job is to chop up long, sticky strings of a protein called von Willebrand factor. Without this enzyme, those strings get too long and sticky, causing platelets to clump together into massive traffic jams (clots) in the tiny, narrow streets of your body's blood vessels. These clots block blood flow, starving organs of oxygen and shredding the red blood cells trying to squeeze through, leading to a dangerous mix of anemia and low platelets.

Usually, doctors can spot this by looking at a blood sample under a microscope and seeing "shattered" blood cells, like glass shards on the road. However, the world recently faced a massive storm: the COVID-19 pandemic. The virus itself causes chaos in the body, making blood sticky and inflaming vessels, which can look exactly like a TTP traffic jam. This creates a confusing puzzle for doctors: Is the patient's blood clotting because of the virus, or is it a rare, deadly case of TTP hiding behind the virus? Knowing the difference is a matter of life and death because the treatments are completely different. If it's just the virus, you treat the infection. If it's TTP, you need an emergency procedure called plasma exchange to wash the bad blood out and replace the missing traffic cop.

The Case of the Masked Mystery

This paper tells the story of a 65-year-old woman who walked into the hospital with a very tricky medical mystery. She had active COVID-19, but she was also suffering from something much more sinister. She was weak, falling down, and her kidneys were failing. When doctors looked at her blood, they saw a mess: her red blood cells were being destroyed (hemolytic anemia), her platelet count was dropping, and she had high levels of a stress marker called LDH. Even worse, she had sudden strokes in multiple parts of her brain, including the cerebellum, which controls balance.

At first, the doctors thought this was just a severe reaction to COVID-19 or perhaps septic shock (a body-wide infection response). The virus was known to cause blood clots, so it seemed like the obvious culprit. But something didn't add up. In a typical severe blood-clotting reaction to infection, the body's "clotting time" tests (PT and INR) usually go haywire. In this patient, those tests were almost normal. Also, when they looked at her blood under a microscope, they only saw a few shattered cells, not the massive pile of glass shards you'd expect in a classic TTP case. This was a red herring—a misleading clue that could have made doctors ignore the real danger.

The team realized that the virus might be wearing a mask, hiding a rare condition called TTP underneath. They suspected that her body had lost its "traffic cop" enzyme, ADAMTS13, completely. Because the test for this enzyme had to be sent to an outside lab, there was a delay. While waiting, the patient's condition got worse. She needed a ventilator to breathe, her kidneys stopped working and required dialysis, and she went into shock.

Finally, the test results arrived, and the diagnosis was confirmed: her ADAMTS13 activity was nearly zero, at a terrifyingly low 0.013%. This proved she had severe TTP, not just a reaction to COVID-19. The doctors immediately started the "cure": a procedure called therapeutic plasma exchange. This is like a giant blood filter that removes the patient's sticky, clot-filled plasma and replaces it with fresh plasma containing the missing enzyme. They also gave her steroids to calm her immune system.

The results were dramatic. Over five days of treatment, her blood counts began to recover. Her hemoglobin rose from 6.8 g/dL to 7.7 g/dL by the time she was ready to leave the hospital, and her platelet count climbed from a low of 66 ×10³/µL back up to 156 ×10³/µL. The stress marker LDH, which had spiked to 906 U/L, dropped steadily down to 199 U/L. She was eventually weaned off the ventilator, moved to a tracheostomy, and sent to rehabilitation.

What This Story Teaches Us

The main takeaway from this paper is a warning to doctors: don't be fooled by the mask. Just because a patient has COVID-19 doesn't mean their blood problems are caused by the virus alone. This paper argues that even if the "shattered cell" count on a microscope slide is low, and even if the patient is critically ill with a virus, doctors must still keep TTP on their list of suspects if the blood shows signs of hemolysis (cell destruction) and low platelets without the usual clotting test abnormalities.

The authors suggest that waiting for the lab results to confirm the missing enzyme can be dangerous. In this case, the delay in getting the 0.013% result meant the patient suffered through severe organ failure before the specific treatment started. The paper concludes that if a doctor suspects TTP, they should start the plasma exchange treatment immediately, even before the test comes back. The presence of the virus does not rule out the rare, deadly enzyme deficiency; in fact, the two can happen at the same time, and missing the TTP diagnosis can be fatal. This case serves as a reminder that in the chaotic world of critical illness, sometimes the rarest explanation is the one that saves the life.